Skip to main content
Premium Trial:

Request an Annual Quote

Sponsored
By F. Hoffmann-La Roche Ltd.

Perspective: Embracing Personalized Healthcare Across the Cancer Care Continuum

Talks and presentations at the virtual ESMO congress demonstrate that the field of cancer research is heading into a new era of tailored treatments. 

By Illumina

Epigenetic Signatures May Indicate COVID-19 Infection and Predict Disease Severity

Disease classifiers based on DNA methylation patterns offer the potential to predict clinical outcomes across infectious diseases.

By Olink

Novel Proteomics Study Finds Potential Biomarkers for Risk and Treatment Response in Diabetes

A high-throughput platform for proteomic profiling with next-generation sequencing (NGS) readout identified early biomarkers for type 2 diabetes and predicted who will best respond to therapeutic intervention.

By Resolve Biosciences

Getting Started in Spatial Biology: What You Need to Know

There is a range of technologies that provide spatial resolution for expressed genes or proteins and allow scientists to look at even the best-characterized biological mechanisms with fresh eyes. No single platform is best for all studies, however; each researcher must consider various factors to choose the best technology for their lab. 

By Swift Biosciences

SARS-CoV-2 Variant Detection From Wastewater Samples Highlights Importance of Complete Genomic Coverage

Recent findings of known and novel SARS-CoV-2 variants underscore the importance of next-generation-sequencing (NGS)-based epidemiology and surveillance research, alongside the need for full genomic coverage of the SARS-CoV-2 virus for NGS studies.

By Biognosys

Advances in the Search for Proteomic Biomarkers in Immuno-oncology: Highlights from AACR and ASCO

New research from Biognosys and collaborators, presented at the 2021 ASCO and AACR conferences, shows how next-generation proteomics can help to predict both outcomes and adverse events from immunotherapy.

By Olink

Linking Genomics with Proteomics to Accelerate the Search for Drug Targets

Several recent studies highlight the promise of combining genomics and proteomics to uncover new, robust drug targets.

By F. Hoffmann-La Roche Ltd.

New TMB Recommendations Help to Guide Treatment Decisions in Oncology

Recent recommendations from the ESMO Precision Medicine Working Group and National Comprehensive Cancer Network, coupled with US Food and Drug Administration review and approval, have highlighted the use of tumor mutational burden testing in clinical practice for a number of different tumor types. 

By Olink

UK Biobank’s Plasma Protein Study Places Proteomics at the Forefront of Multiomic Disease Research

The UK Biobank’s recent decision to add proteome information to its genetic database exemplifies a recent trend to use big data and a multiomics approach to better understand drugs and disease. 

By Biognosys

Going Beyond Genomics with Next-Generation Proteomics to Accelerate Precision Oncology

In recent years, the field of proteomics has undergone a transformation, enabling quantitative analysis of more than 10,000 proteins across thousands of samples, while advances in structural chemoproteomics allow researchers to map drug binding sites with unprecedented resolution. These next-generation proteomics approaches are driving significant progress in precision oncology.